The Antibody Society is an international, non-profit trade association serving individuals and organizations involved in antibody-related research and development. We research and analyze data on targeted therapeutics developed by the biopharmaceutical industry, and distribute our results and commentary via the Society’s website, presentations and publications. The Society hosts educational webinars and Symposia, and serves as the home for the Adaptive Immune Receptor Repertoire (AIRR) Community, which focuses on the generation, use, sharing and standardization of next-generation sequencing of antibodies and T cell receptors. In addition, we engage with international agencies on matters of importance to the antibody community.

Our members serve as the Scientific Advisors for the Antibody Engineering & Therapeutics conferences. The scientific programs for the meetings are designed by our Meetings Committee.

The Antibody Society Meeting Committee Members

• Katherine Harris, Ph.D., Chief Development Officer, Rondo Therapeutics (Chair)
• Jonathan Sockolosky, Ph.D., Director, Company Value Creation, Curie.Bio
• Pam Borghardt. AIRR Community Executive Director
• James A. Ernst, Ph.D., Senior Director, Head of Development Sciences, Xencor
• Jan Terje Andersen, Ph.D., Professor, University of Oslo and Group Leader Oslo University Hospital, Norway
• Jamie Spangler, Ph.D., Assistant Professor, Biomedical Engineering and Chemical & Biomolecular Engineering, Johns Hopkins University
• Stephen Beers, Ph.D., Professor of Immunology and Immunotherapy, Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton, United Kingdom
• Mitchell Ho, Ph.D., Senior Investigator, Laboratory of Molecular Biology, NIH NCI

Antibody Engineering & Therapeutics Europe 2023 Advisors

• Katherine Harris, Ph.D., Chief Development Officer, Rondo Therapeutics; Meetings Committee chair, The Antibody Society
• Sally Ward, Ph.D., Professor and Director, University of Southampton, United Kingdom; President, The Antibody Society
• Paul W.H.I. Parren, Ph.D., Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center and EVP and Head of R&D, Lava Therapeutics, The Netherlands; Board of Directors chair, The Antibody Society
• Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom; Director, The Antibody Society
• Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, Switzerland; Member, The Antibody Society
• Sai Reddy, Ph.D., Associate Professor, Department of Biosystems Science and Engineering, ETH Zurich/Swiss Federal Institute of Technology, Switzerland

Antibody Engineering & Therapeutics Europe 2023 Guest Session Chairs

• Benjamí Oller-Salvia, Ph.D., Assistant Professor at IQS Barcelona, Ramon Llull University, Spain
• Rene Hoet, Ph.D., Chief Innovations Officer, FairJourney Biologics, Portugal; Member, The Antibody Society
• Dario Neri, Ph.D., CEO and CSO, Philogen, Switzerland; Member, The Antibody Society
• Stephen Beers, Ph.D., Professor of Immunology and Immunotherapy, Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton, United Kingdom; Member, The Antibody Society
• Alain Beck, Ph.D., Senior Director, Biologics CMC and Developability, Pierre Fabre Group, France; Member, The Antibody Society
• Nicolas Fischer, Ph.D., CEO, Light Chain Bioscience, Switzerland; Member, The Antibody Society
• Marina Bacac, Ph.D., Head of Cancer Immunotherapy Department, Roche pRED, Switzerland
• Cédric R. Weber, Ph.D., Director of Data Science and Bioinformatics, Alloy Therapeutics, Inc., Switzerland; Member, The Antibody Society